Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Incyte’s latest 10-K means sifting through pages of clinical-trial data, FDA milestones, and royalty tables—details that can obscure crucial signals like how much Jakafi revenue offsets soaring R&D costs. If finding Incyte insider trading Form 4 transactions before a pivotal read-out feels daunting, you’re not alone.
Stock Titan’s AI reads every Incyte quarterly earnings report 10-Q filing, 8-K material events explained, and the full Incyte annual report 10-K simplified so you don’t have to. Our platform delivers real-time alerts the moment an Incyte Form 4 insider transactions real-time notice posts to EDGAR, then translates legal jargon into plain English. Need a quick brief on trial spend vs. cash reserves? Our AI-powered summaries surface it in one click, making understanding Incyte SEC documents with AI part of your routine.
Use the filing types below to answer the questions professionals ask every quarter:
- 10-Q: Track segment revenue, pipeline spend, and compare results with our Incyte earnings report filing analysis.
- 10-K: Review patent cliffs, market-size assumptions, and risk factors—Incyte SEC filings explained simply.
- Form 4: Monitor Incyte executive stock transactions Form 4 for buying or selling patterns.
- DEF 14A: See the Incyte proxy statement executive compensation section without hunting through tables.
- 8-K: Get Incyte 8-K material events explained within minutes of release.
Whether you’re gauging partnership royalty streams or confirming cash runway, Stock Titan turns dense biotech disclosures into actionable knowledge—before the market reacts.
Incyte Genomics Inc (INCY) filed a Form 144 reporting a proposed sale of 277 common shares on 08/15/2025 through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of $24,046.37 and shows 195,276,145 shares outstanding, and the shares were acquired the same day via a stock option exercise with payment in cash.
The filing also discloses five recent sales by Sheila Denton within the prior three months: 1,795 shares on 06/03/2025; 599 on 07/02/2025; 3,330 on 07/15/2025; 785 on 07/16/2025; and 598 on 08/04/2025, with gross proceeds reported for each sale. The filer certifies no undisclosed material adverse information and the form identifies Morgan Stanley as broker of record.
Incyte Genomics' Form 144 records a proposed sale of 75,963 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $6,267,540.00. The shares were acquired via a stock option exercise on 08/13/2025 and payment was made in cash.
The filing also lists insider sales by Barry Flannelly totaling 27,472 shares in the past three months for gross proceeds of $2,040,893.53. The issuer reports 195,276,145 shares outstanding, so the proposed sale equals approximately 0.039% of outstanding shares. The document contains no earnings, guidance, or other operational details.
Incyte Genomics' Form 144 discloses a proposed sale of 14,037 common shares with an aggregate market value of $1,122,969.83, to be sold through Morgan Stanley Smith Barney on 08/12/2025 on NASDAQ. The filing states these shares were acquired on 08/12/2025 through a stock option exercise and paid for in cash.
The notice also lists recent sales by BARRY FLANNELLY totaling 13,435 shares in July 2025, generating gross proceeds of $917,923.70. The filing shows 195,276,145 shares outstanding and includes the filer's certification that they do not possess undisclosed material adverse information.
Form 3 filing snapshot: On 21 Jul 2025 Patrick A. Mayes—newly appointed EVP & Chief Scientific Officer of Incyte Corp. (INCY)—submitted his initial statement of beneficial ownership.
- Direct equity: 67,388 common shares, the bulk of which are restricted stock units scheduled to vest between 2025-2028.
- Derivative exposure: 57,080 employee stock options across 15 grants; strike prices range from $61.18 to $106.47 with expirations from 2027-2035. Most awards are either fully vested or vest monthly/annually over four years.
The filing establishes Mayes as a Section 16 insider and documents equity-based incentives that align his compensation with shareholder value. No purchases or sales occurred, so immediate market impact is minimal.
FAQ
What is the current stock price of Incyte (INCY)?
What is the market cap of Incyte (INCY)?
